141MO Pathological Response and Early Survival Data According to TNBCtype4 Classifier in Operable Triple-Negative Breast Cancer (TNBC) Treated with Neoadjuvant Carboplatin and Docetaxel

I. Echavarria Diaz-Guardamino,S. Lopez-Tarruella Cobo,M. Del Monte-Millan,E. Alvarez,Y. Jerez,F. Moreno Anton,J. A. Garcia Saenz,T. Massarrah,I. Ocana,M. Cebollero,A. I. Ballesteros Garcia,U. Bohn Sarmiento,H. Gomez,H. A. Fuentes,B. Herrero Lopez,S. Gamez Casado,O. Bueno, M. J. Jimenez-Santos,M. Roche-Molina,M. Martin Jimenez

Annals of oncology（2022）

引用 2|浏览19

暂无评分

摘要

The identification of predictive biomarkers of response to neoadjuvant chemotherapy (NACT) is an unmet need in early-stage TNBC. Transcriptomic classification according to TNBCtype-4 classifier has shown predictive value, and we aimed to validate our previous results (Echavarria I et al, CCR 2018) in terms of response and long-term outcomes in a larger cohort.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要